ADMA Biologics announced the U.S. Food and Drug Administration, FDA, has approved the Company’s supplemental Biologics License Application submitted under section 351 of the Public Health Service Act for BIVIGAM. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of BIVIGAM’s prescribing information to expand the primary humoral immunodeficiency indication to pediatric patients 2 years of age and older. “We are pleased to announce that BIVIGAM has received FDA approval for treating PI in patients aged 2 years and older. Previously, the indication for BIVIGAM was restricted to PI patients aged 12 years and older,” said Adam Grossman, President and Chief Executive Officer of ADMA. “This expanded label for BIVIGAM allows ADMA to actively address the treatment needs of younger PI patients earlier in their treatment journey. In the periods ahead, we look forward to offering BIVIGAM as an FDA-approved treatment option for these pediatric PI patients,” concluded Mr. Grossman.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics receives FDA approval for tenth plasma collection cent er
- ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
- ADMA Biologics boosts FY23 revenue view to exceed $250M from $240M previously
- ADMA Biologics reports Q3 EPS 1c, consensus 1c
- ADMA Upcoming Earnings Report: What to Expect?